Are you developing exosome-based therapeutics or exploring the potential of extracellular vesicles (EVs) in advanced therapies? This webinar delivers a comprehensive, science-driven framework for EV characterization, letting you to overcome key development and manufacturing challenges and accelerate your path to clinical success.
Key Takeaways
- A clear, actionable framework for EV characterization and process development
- Practical solutions to accelerate your EV program from research to clinic
- Real-world examples and Q&A with industry experts
- Access to on-demand resources and follow-up support
What You'll Learn
The Critical Role of Analytics
Discover how advanced analytical tools underpin every stage of EV development from defining identity, purity, potency, and safety, to ensuring process scalability and regulatory compliance.
End-to-End Solutions for EV Therapeutics
Learn about Lonza’s unique, integrated platform supporting innovation, development, CGMP manufacturing, and standalone characterization designed to help you scale from early-stage research to commercial launch.
Overcoming Industry Challenges
Common hurdles we discuss:
- Lack of robust characterization and purification methods
- Process scalability and GMP manufacturing expertise
- Optimal formulation strategies
- Access to gene editing, cargo loading, and functional assay development
Innovations in EV Manufacturing
We'll highlight Lonza's state-of-the-art technologies for cell line engineering, process optimization, and advanced loading/decoration of EVs for therapeutic delivery.
Regulatory and Clinical Guidance
Understand how Lonza's regulatory team supports clients in navigating the evolving EV regulatory landscape, leveraging real-world IND and clinical submission experience.
Who Should Attend?
This webinar is essential for:
- Biotech and pharma leaders developing exosome/EV-based therapeutics
- R&D scientists and process development teams seeking scalable, GMP-ready solutions
- Regulatory and quality professionals navigating the evolving EV landscape
- Investors and business development professionals evaluating the potential of EV technologies
- Anyone interested in the future of cell and gene therapy manufacturing
